|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RRS1 |
Gene summary for RRS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RRS1 | Gene ID | 23212 |
| Gene name | ribosome biogenesis regulator 1 homolog | |
| Gene Alias | RRS1 | |
| Cytomap | 8q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000027 | UniProtAcc | Q15050 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23212 | RRS1 | LZE2T | Human | Esophagus | ESCC | 1.14e-05 | 4.11e-01 | 0.082 |
| 23212 | RRS1 | LZE4T | Human | Esophagus | ESCC | 4.09e-07 | 1.85e-01 | 0.0811 |
| 23212 | RRS1 | LZE7T | Human | Esophagus | ESCC | 2.65e-04 | 4.48e-02 | 0.0667 |
| 23212 | RRS1 | LZE8T | Human | Esophagus | ESCC | 5.70e-05 | 3.90e-02 | 0.067 |
| 23212 | RRS1 | LZE24T | Human | Esophagus | ESCC | 1.37e-03 | 1.54e-01 | 0.0596 |
| 23212 | RRS1 | P2T-E | Human | Esophagus | ESCC | 1.64e-12 | 2.29e-01 | 0.1177 |
| 23212 | RRS1 | P4T-E | Human | Esophagus | ESCC | 8.78e-10 | 4.44e-01 | 0.1323 |
| 23212 | RRS1 | P5T-E | Human | Esophagus | ESCC | 7.15e-16 | 3.27e-01 | 0.1327 |
| 23212 | RRS1 | P8T-E | Human | Esophagus | ESCC | 3.95e-09 | 2.87e-02 | 0.0889 |
| 23212 | RRS1 | P9T-E | Human | Esophagus | ESCC | 3.41e-10 | 2.79e-01 | 0.1131 |
| 23212 | RRS1 | P10T-E | Human | Esophagus | ESCC | 2.81e-10 | 2.00e-01 | 0.116 |
| 23212 | RRS1 | P11T-E | Human | Esophagus | ESCC | 2.67e-03 | 5.34e-01 | 0.1426 |
| 23212 | RRS1 | P12T-E | Human | Esophagus | ESCC | 1.15e-16 | 2.89e-01 | 0.1122 |
| 23212 | RRS1 | P15T-E | Human | Esophagus | ESCC | 4.52e-16 | 4.66e-01 | 0.1149 |
| 23212 | RRS1 | P16T-E | Human | Esophagus | ESCC | 1.48e-16 | 5.65e-01 | 0.1153 |
| 23212 | RRS1 | P17T-E | Human | Esophagus | ESCC | 7.37e-03 | 3.59e-01 | 0.1278 |
| 23212 | RRS1 | P20T-E | Human | Esophagus | ESCC | 1.37e-15 | 3.72e-01 | 0.1124 |
| 23212 | RRS1 | P21T-E | Human | Esophagus | ESCC | 3.70e-22 | 6.37e-01 | 0.1617 |
| 23212 | RRS1 | P22T-E | Human | Esophagus | ESCC | 7.54e-25 | 4.21e-01 | 0.1236 |
| 23212 | RRS1 | P23T-E | Human | Esophagus | ESCC | 9.72e-27 | 7.82e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00550726 | Cervix | CC | iron ion homeostasis | 19/2311 | 85/18723 | 6.88e-03 | 3.74e-02 | 19 |
| GO:00550768 | Cervix | CC | transition metal ion homeostasis | 27/2311 | 138/18723 | 9.89e-03 | 4.85e-02 | 27 |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0006913110 | Esophagus | ESCC | nucleocytoplasmic transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:0051169110 | Esophagus | ESCC | nuclear transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:0051168110 | Esophagus | ESCC | nuclear export | 126/8552 | 154/18723 | 1.88e-20 | 2.65e-18 | 126 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0042274111 | Esophagus | ESCC | ribosomal small subunit biogenesis | 67/8552 | 73/18723 | 6.62e-17 | 5.38e-15 | 67 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RRS1 | SNV | Missense_Mutation | c.49N>A | p.Glu17Lys | p.E17K | Q15050 | protein_coding | tolerated(0.21) | benign(0.359) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| RRS1 | SNV | Missense_Mutation | c.854N>T | p.Thr285Ile | p.T285I | Q15050 | protein_coding | tolerated(0.08) | possibly_damaging(0.597) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RRS1 | deletion | Frame_Shift_Del | c.140delC | p.Pro47ArgfsTer42 | p.P47Rfs*42 | Q15050 | protein_coding | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| RRS1 | deletion | Frame_Shift_Del | c.135delN | p.Pro47ArgfsTer42 | p.P47Rfs*42 | Q15050 | protein_coding | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| RRS1 | deletion | Frame_Shift_Del | c.135delN | p.Pro47ArgfsTer42 | p.P47Rfs*42 | Q15050 | protein_coding | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| RRS1 | SNV | Missense_Mutation | novel | c.410N>A | p.Ser137Asn | p.S137N | Q15050 | protein_coding | tolerated(0.53) | benign(0.046) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| RRS1 | SNV | Missense_Mutation | novel | c.1031C>T | p.Ser344Phe | p.S344F | Q15050 | protein_coding | deleterious_low_confidence(0.02) | benign(0.062) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RRS1 | SNV | Missense_Mutation | novel | c.247N>T | p.Arg83Cys | p.R83C | Q15050 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-AX-A3FS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RRS1 | SNV | Missense_Mutation | novel | c.470T>G | p.Leu157Arg | p.L157R | Q15050 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RRS1 | SNV | Missense_Mutation | rs775749259 | c.1031C>A | p.Ser344Tyr | p.S344Y | Q15050 | protein_coding | deleterious_low_confidence(0.02) | benign(0.062) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |